Controlled comparison of trebenzomine with doxepin as an antidepressant-anxiolytic.
Trebenzomine, a new psychotropic drug, was compared with doxepin in the treatment of anxiety and depression. The study was a three-week, double-blind trial involving 26 psychoneurotic inpatients. Multiple ratings by physician, nurse, and patient all concurred that the 2 drugs produced significant improvement in both depressive and anxious symptomatology. No significant differences were found between the 2 drugs either in terms of rate or degree of improvement or incidence of side effects. Further investigation of trebenzomine for anxious depression is warranted.
D000328:Adult; D001007:Anxiety / Q000188:drug therapy*; D001578:Benzopyrans / Q000627:therapeutic use*; D002839:Chromans / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy*; D004311:Double-Blind Method; D004316:Doxepin / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009497:Neurotic Disorders / Q000188:drug therapy; D011569:Psychiatric Status Rating Scales
D001578:Benzopyrans; D002839:Chromans; D004316:Doxepin; C006122:trebenzomine